The use of rabbit intestinal permeability as an in vitro assay in the search for orally active GPIIb/IIIa antagonists

被引:1
|
作者
Samanen, JM
Lee, CP
Smith, PL
Bondinell, WE
Calvo, RR
Jakas, DR
Newlander, KA
Parker, M
Uzinskas, I
Yellin, TO
Nichols, AJ
机构
[1] SMITHKLINE BEECHAM PHARMACEUT,DEPT DRUG DELIVERY,KING OF PRUSSIA,PA 19406
[2] SMITHKLINE BEECHAM PHARMACEUT,DEPT PHARMACOL,KING OF PRUSSIA,PA 19406
关键词
absorption; peptides; transport; permeability; pharmacophore model; GPIIb/IIIa antagonists; oral activity; bioavailability; Ussing Chamber;
D O I
10.1016/S0169-409X(96)00431-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A series of potent, high affinity GPIIb/IIIa antagonists were evaluated for intestinal permeability in vitro using rabbit intestinal strips mounted in the Ussing Chamber. In this series of compounds, structural modifications were found to impact intestinal permeability. In general, modifications that would contribute to lipophilicity (e.g. olefinic replacement for amide, phenethyl or isopropyl for methyl) did not enhance permeability. When these intestinal permeabilities were compared to mannitol, which displays similar to 20% oral bioavailability in humans (Laker et al. (1982) fur. J. Clin. Invest. 12, 485-491), it was possible then to select compounds with permeabilities comparable to mannitol for oral (intraduodenal) evaluation in conscious dogs. The influence of intestinal permeability on oral efficacy can be observed within a series of compounds with closely related structures, but is less discernable in across structural series. Intestinal permeability data can provide meaningful, reliable data that can help in analog design and in the selection of compounds for oral evaluation.
引用
收藏
页码:133 / 142
页数:10
相关论文
共 50 条
  • [21] In vitro permeability screening for identification of orally bioavailable endothelin receptor antagonists
    Ellens, H
    Eddy, EP
    Lee, CP
    Dougherty, P
    Lago, A
    Xiang, JN
    Elliott, JD
    Cheng, HY
    Ohlstein, E
    Smith, PL
    ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) : 99 - 109
  • [22] Synthesis and pharmacology of orally active, isoxazoline glycoprotein IIb-IIIa receptor antagonists
    Xue, CB
    Wityak, J
    Sielecki, TM
    Cain, GA
    Liu, J
    Bostrom, LL
    DiMeo, SV
    Higley, CA
    Lalka, GK
    Tobin, AE
    Frietze, WE
    Emmett, G
    Mousa, SA
    Sze, JY
    Thoolen, MJ
    Reilly, TM
    DeGrado, WF
    Olson, RE
    Wexler, RR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 132 - MEDI
  • [23] Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists
    Sall, DJ
    Arfsten, AE
    Bastian, JA
    Denney, ML
    Harms, CS
    McCowan, JR
    Morin, JM
    Rose, JW
    Scarborough, RM
    Smyth, MS
    Um, SL
    Utterback, BG
    Vasileff, RT
    Wikel, JH
    Wyss, VL
    Jakubowski, JA
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (18) : 2843 - 2857
  • [24] Reversibility of platelet inhibition associated with small molecule, competitive GPIIb/IIIa antagonists: An in vitro model for clinical management strategies
    Becker, RC
    Li, YF
    Spencer, FA
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 344A - 345A
  • [25] A NEW METHOD FOR MEASUREMENT OF PLASMA-CONCENTRATION OF ORALLY-ACTIVE GLYCOPROTEIN IIB/IIIA ANTAGONISTS
    SALYERS, AK
    SZALONY, JA
    TAITE, BB
    HAAS, NF
    MEHROTRA, DV
    FEIGEN, LP
    NICHOLSON, NS
    THROMBOSIS RESEARCH, 1994, 75 (04) : 409 - 417
  • [26] In vitro dose response to different GPIIb/IIIa-antagonists:: Inter-laboratory comparison of various platelet function tests
    Harder, S
    Klinkhardt, U
    Graff, J
    Westrup, D
    Kirchmaier, CM
    Glusa, E
    Mascelli, MA
    Marciniak, SJ
    Just, A
    Lösche, W
    Breddin, HK
    THROMBOSIS RESEARCH, 2001, 102 (01) : 39 - 48
  • [27] The use of the point of care Helena ICHOR/Plateletworks® and the accumetrics Ultegra® RPFA for assessment of platelet function with GPIIb-IIIa antagonists
    White, MM
    Krishnan, R
    Kueter, TJ
    Jacoski, MV
    Jennings, LK
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2005, 18 (03) : 163 - 169
  • [28] The Use of the Point of Care Helena ICHOR/Plateletworks® and the Accumetrics Ultegra® RPFA for Assessment of Platelet Function with GPIIb-IIIa Antagonists
    Melanie M. White
    Rajini Krishnan
    Teddi J. Kueter
    Mary V. Jacoski
    Lisa K. Jennings
    Journal of Thrombosis and Thrombolysis, 2004, 18 : 163 - 169
  • [29] Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists
    Mehrotra, MM
    Heath, JA
    Smyth, MS
    Pandey, A
    Rose, JW
    Seroogy, JM
    Volkots, DL
    Nannizzi-Alaimo, L
    Park, GL
    Lambing, JL
    Hollenbach, SJ
    Scarborough, RM
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (08) : 2037 - 2061
  • [30] Modulation of intestinal permeability by cannabinoids, cytokines and cannabinoid receptor antagonists in a novel in vitro model
    Alhamoruni, A.
    Lund, J. N.
    Larvin, M.
    O'Sullivan, S.
    BRITISH JOURNAL OF SURGERY, 2010, 97 : 29 - 30